These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 20448071

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
    Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC.
    Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Hemoglobin level variability: anemia management among variability groups.
    Gilbertson DT, Peng Y, Bradbury B, Ebben JP, Collins AJ.
    Am J Nephrol; 2009 May; 30(6):491-8. PubMed ID: 19786739
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [Abstract] [Full Text] [Related]

  • 30. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
    Fatodu H.
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
    [Abstract] [Full Text] [Related]

  • 33. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS, Widjaja D.
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [Abstract] [Full Text] [Related]

  • 34. [Management of anemia in chronic kidney disease].
    López Gómez JM.
    Nefrologia; 2008 Jun; 28 Suppl 3():63-6. PubMed ID: 19018741
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG.
    Circulation; 2006 Jun 13; 113(23):2713-23. PubMed ID: 16754803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.